Novartis Reaches $185M Deal Over Off-Label Claims
Novartis AG announced Tuesday that it will pay a $185 million fine to resolve criminal allegations that the drugmaker engaged in off-label marketing and promotion of epilepsy drug Trileptal....To view the full article, register now.
Already a subscriber? Click here to view full article